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Résumé en
anglais
Giant cell arteritis (GCA) affects middle-sized or large arteries in individuals over 50
years of age. GCA is characterized by a combination of focal inflammation
responsible for arterial stenosis or occlusion and of systemic inflammation
manifesting as polymyalgia rheumatica, a decline in general health, and
inflammatory anemia. In addition to the typical involvement of the branches of the
external carotid arteries, relatively common sites of involvement include the aorta,
most notably in its thoracic segment, and the subclavian, axillary, brachial,
vertebral, and femoral arteries. The treatment of GCA rests on daily glucocorticoid
administration, which should be started on an emergency basis in patients with
incipient visual impairments (diplopia or amaurosis fugax). The duration of
glucocorticoid therapy is unpredictable and side effects are common. Initial
megadose glucocorticoid therapy does not decrease subsequent glucocorticoid
requirements. Glucocorticoid therapy regulates the Th17 pathway, which is involved
in the prominent vascular and systemic manifestations; but not the Th1 pathway,
which may underlie the chronic course of the disease (whereas aspirin, in addition to
decreasing platelet aggregation, blocks the Th1 mediator interferon-gamma).
Although GCA is classically described as resolving within 1 to 3 years, clinical
practice often teaches otherwise. Many patients experience rebound abnormalities
in laboratory tests and/or relapses, and some of them have recurrences after an
apparently full recovery. Histological documentation is useful to confirm the
diagnosis. The effect of methotrexate and TNFα antagonists is modest at best. A few
patients have responded to tocilizumab, which suppresses IL-6, a key cytokine in
GCA. Life expectancy in GCA patients is similar to that in same-age controls except
for a slight excess in vascular mortality shortly after the diagnosis.
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